Island -
islandsk -
LYFJASTOFNUN (Icelandic Medicines Agency)
oftaquix augndropar, lausn í stakskammtaíláti 5 mg/ml
santen oy* - levofloxacinum hemihýdrat - augndropar, lausn í stakskammtaíláti - 5 mg/ml
Island -
islandsk -
LYFJASTOFNUN (Icelandic Medicines Agency)
taflotan augndropar, lausn í stakskammtaíláti 15 míkróg/ml
santen oy* - tafluprostum inn - augndropar, lausn í stakskammtaíláti - 15 míkróg/ml
Island -
islandsk -
LYFJASTOFNUN (Icelandic Medicines Agency)
taflotan sine (taflotan) augndropar, lausn 15 míkróg/ml
santen oy* - tafluprostum inn - augndropar, lausn - 15 míkróg/ml
Island -
islandsk -
LYFJASTOFNUN (Icelandic Medicines Agency)
timosan depot í stakskammtaíláti augnhlaup í stakskammtaíláti 1 mg/g
santen oy* - timololum maleat - augnhlaup í stakskammtaíláti - 1 mg/g
Den europeiske union -
islandsk -
EMA (European Medicines Agency)
entresto
novartis europharm limited - sacubitril, valsartan - hjartabilun - ace ii hemla, önnur sturtu, umboðsmenn starfa á renín-ace kerfi - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.
Den europeiske union -
islandsk -
EMA (European Medicines Agency)
neparvis
novartis europharm limited - sacubitril, valsartan - hjartabilun - lyf sem hafa áhrif á renín-angíótensín kerfið - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.
Den europeiske union -
islandsk -
EMA (European Medicines Agency)
roclanda
santen oy - latanoprost, netarsudil mesilate - glaucoma, open-angle; ocular hypertension - augnlækningar - roclanda is indicated for the reduction of elevated intraocular pressure (iop) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient iop reduction.
Island -
islandsk -
LYFJASTOFNUN (Icelandic Medicines Agency)
taptiqom sine (taptiqom) augndropar, lausn 15 microg/ml + 5 mg/ml
santen oy* - tafluprostum inn; timololum maleat - augndropar, lausn - 15 microg/ml + 5 mg/ml
Island -
islandsk -
LYFJASTOFNUN (Icelandic Medicines Agency)
cosopt sine augndropar, lausn 20 mg/ml+5 mg/ml
santen oy* - dorzolamidum hýdróklóríð; timololum maleat - augndropar, lausn - 20 mg/ml+5 mg/ml
Island -
islandsk -
LYFJASTOFNUN (Icelandic Medicines Agency)
taptiqom augndropar, lausn í stakskammtaíláti 15 microg/ml + 5 mg/ml
santen oy - tafluprostum inn; timololum maleat - augndropar, lausn í stakskammtaíláti - 15 microg/ml + 5 mg/ml